Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial, Reducing Disease Progression Risk by 49%

Clinical Trial Success:
Summit Therapeutics' Phase 3 HARMONi-2 trial demonstrated that ivonescimab significantly outperformed pembrolizumab (Keytruda) in reducing the risk of disease progression or death by 49% in patients with PD-L1 positive non-small cell lung cancer (NSCLC).

Progression-Free Survival (PFS):
Ivonescimab extended PFS to a median of 11.14 months compared to 5.82 months for Keytruda, showing a statistically significant improvement.

Secondary Endpoints:
Ivonescimab also showed better overall response rates (50% vs. 38.5%) and disease control rates (89.9% vs. 70.5%) compared to Keytruda.

Future Plans:
Summit plans to initiate the Phase 3 HARMONi-7 trial in early 2025 to compare ivonescimab monotherapy with Keytruda monotherapy in patients with metastatic NSCLC and high PD-L1 expression.

Analyst Caution:
Despite the promising results, analysts advise caution due to the trial being conducted entirely in China and the need for more U.S. data before FDA approval can be considered.